Sun Pharma signs $55m manufacturing deal for investigational psoriasis drug

05:15 EDT 4 Jul 2017 | Pharmafile

India’s biggest pharma firm has signed a $55 million long-term manufacturing deal with Korea’s Samsung BioLogics for Tildrakizumab, an investigational IL-23p19 inhibitor currently being assessed for efficacy in treating moderate to severe plaque psoriasis.

"The agreement was entered into by Sun Pharma's wholly-owned subsidiary and Samsung BioLogics," the two companies said in a joint statement. As part the deal, Samsung BioLogics will offer its manufacturing expertise and infrastructure to produce products in the Tildrakizumab pipeline.

read more

Original Article: Sun Pharma signs $55m manufacturing deal for investigational psoriasis drug


More From BioPortfolio on "Sun Pharma signs $55m manufacturing deal for investigational psoriasis drug"

Quick Search


Relevant Topics

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Alzumab (Itolizumab)
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...